Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis
复制标题
DOI：
10.1136/ard.2004.023119
复制
发表时间：
2005-02-01
影响因子：
27.4
通讯作者：
Barerra, P
中科院分区：
文献类型：
--
作者：
Popa, C;Netea, MG;Barerra, P
背景：众所周知，肿瘤坏死因子 (TNF) 会增加白细胞介素 (IL) 6 和 C 反应蛋白 (CRP) 的浓度，诱导血脂发生致动脉粥样硬化变化，并可能增加类风湿性关节炎 (RA) 和其他炎症性疾病患者的心血管风险。目的：评估抗 TNF 治疗是否会改变 RA 患者的心血管风险状况。方法：对 33 名 RA 患者的脂蛋白谱以及炎症标志物 CRP 和 IL6 进行了研究。使用人抗 TNF 单克隆抗体（D2E7、阿达木单抗、Humira）治疗 RA，并在治疗 2 周之前和之后，对 13 名 RA 患者给予安慰剂。结果：在抗 TNF 治疗组中，治疗 2 周后 HDL 胆固醇的平均 (SD) 浓度显着升高 (0.86 (0.30) mmol/l v 0.98 (0.33) mmol/l，p
Background: Tumour necrosis factor (TNF) is known to increase the concentrations of interleukin (IL) 6 and C reactive protein (CRP) and to induce proatherogenic changes in the lipid profile and may increase the cardiovascular risk of patients with rheumatoid arthritis (RA) and other inflammatory disorders.Objective: To assess whether anti-TNF therapy modifies the cardiovascular risk profile in patients with RA.Methods: The lipoprotein spectrum and the inflammation markers CRP and IL6 were investigated in 33 patients with RA treated with human anti-TNF monoclonal antibodies (D2E7, adalimumab, Humira) and 13 patients with RA given placebo, before and after 2 weeks' treatment.Results: In the anti-TNF treated group, the mean (SD) concentrations of HDL-cholesterol were significantly higher after 2 weeks' treatment (0.86 (0.30) mmol/l v 0.98 (0.33) mmol/l, p